Cardiff Oncology shifts lead mCRC program to first-line; Q3 cash $81.4M

Cardiff Oncology, Inc.

2023-Q3 EPS reported -$0.72 revenue$332,000

Lead onvansertib program advances to first-line RAS-mutated mCRC; Pfizer Ignite to execute Phase 2 CRDF-004 trial.
FDA agreed on ORR as interim endpoint for accelerated approval; Phase 3 registrational trial planned contingent on CRDF-004.
mPDAC CRDF-001: ORR 19% (4/21 evaluable) vs historical 7.7%; mPFS 5.0 mo vs 3.1 mo for SoC alone.
Phase 2 SCLC monotherapy cleared to continue enrollment after safety review of first six patients.
Cash, equivalents, and short-term investments $81.4M; net cash burn Q3 $8.0M; runway into 2025.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cardiff Oncology, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 2, 2023, Cardiff Oncology, Inc. issued a press release announcing company highlights and financial results for the third quarter ended September 30, 2023.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Cardiff Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-036386

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.